Work

Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.501

Authors: Neil J. Shah, Rahul Ravilla, Andrew J. Osterland, Karen Todoroff, Ching-Yu Wang, Pratik Rane, Hakim Saal, Ding Wang, Robert J. Motzer

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York Oncology Hematology, The US Oncology Network, Merck & Co., Inc., Rahway, NJ, USA (United States), Eisai (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Merck

OpenAlex ID: W4407702115

Cites:

Cited by: 1

Related to: 10